TY - JOUR
T1 - Nasopharyngeal cancer WHO type II-III
T2 - Monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy
AU - Franchin, G.
AU - Vaccher, E.
AU - Talamini, R.
AU - Gobitti, C.
AU - Minatel, E.
AU - Politi, D.
AU - Sartor, G.
AU - Trovò, M. G.
AU - Barzan, L.
PY - 2002
Y1 - 2002
N2 - The aim of this study is to assess the impact of prognostic factors in patients with locoregionally advanced nasopharyngeal cancer (NPC), WHO type II-III, treated with two different radiation therapy (RT) schedules: standard radiation therapy (SRT), and accelerated hyperfractionated radiation therapy (HART), with or without sequential chemotherapy. Between January 1986 and December 1999, 78 consecutive NPC patients were treated either with SRT (until August 1993) or with HART (from September 1993). Of the 78 patients, 60 were males and 18 females, the median age was 56 years (range 14-83). Nine patients had a non-keratinizing carcinoma (WHO type II) and 69 an undifferentiated carcinoma (WHO type III). Five-year overall survival rate (OS) was 62%. Two months after RT, 73 patients were in complete remission. Disease-free survival (DFS) rates at 5 years were: 85% for the HART and 59% for the SRT group, respectively. A multivariate analysis, age (hazard ratio, HR = 4.17 for ≥ 60 vs.
AB - The aim of this study is to assess the impact of prognostic factors in patients with locoregionally advanced nasopharyngeal cancer (NPC), WHO type II-III, treated with two different radiation therapy (RT) schedules: standard radiation therapy (SRT), and accelerated hyperfractionated radiation therapy (HART), with or without sequential chemotherapy. Between January 1986 and December 1999, 78 consecutive NPC patients were treated either with SRT (until August 1993) or with HART (from September 1993). Of the 78 patients, 60 were males and 18 females, the median age was 56 years (range 14-83). Nine patients had a non-keratinizing carcinoma (WHO type II) and 69 an undifferentiated carcinoma (WHO type III). Five-year overall survival rate (OS) was 62%. Two months after RT, 73 patients were in complete remission. Disease-free survival (DFS) rates at 5 years were: 85% for the HART and 59% for the SRT group, respectively. A multivariate analysis, age (hazard ratio, HR = 4.17 for ≥ 60 vs.
KW - Accelerated hyperfractionated radiation therapy
KW - Nasopharyngeal carcinoma WHO type II-III
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0036178558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036178558&partnerID=8YFLogxK
U2 - 10.1016/S1368-8375(01)00034-3
DO - 10.1016/S1368-8375(01)00034-3
M3 - Article
C2 - 11854060
AN - SCOPUS:0036178558
VL - 38
SP - 137
EP - 144
JO - Oral Oncology
JF - Oral Oncology
SN - 1368-8375
IS - 2
ER -